2-氟-5-[(4-氧代-3,4-二氢酞嗪-1-基)甲基]苯甲酸的合成工艺改进
|
摘要
使用较为价廉的邻苯二甲酰亚胺作为起始原料,经选择性还原、加成、水解,合成了目标化合物2-氟-5-[(4-氧代-3,4-二氢酞嗪-1-基)甲基]苯甲酸,总收率达60.5%。相应各步反应条件得以优化,用质谱、核磁共振氢谱确定了目标化合物的结构。该方法起始原料价廉易得,操作简单易行,具有工业化应用前景。
2-fluoro-5-[(4-oxo-3 h-phthalazin-1-yl) methyl]Benzoic acid was synthesized by condensing Phthalimide,and followed by reduction,addition reaction,hydrolysisformation. The total yield was 60. 5%.Structures of the target product were verified by MS and ~1HNMR. The reaction condition was mild. The optimum synthetic procedure was synthesized with materials of lower cost,and was suitable for industrial production.
2-fluoro-5-[(4-oxo-3 h-phthalazin-1-yl) methyl]Benzoic acid was synthesized by condensing Phthalimide,and followed by reduction,addition reaction,hydrolysisformation. The total yield was 60. 5%.Structures of the target product were verified by MS and ~1HNMR. The reaction condition was mild. The optimum synthetic procedure was synthesized with materials of lower cost,and was suitable for industrial production.
引文
[1]皮如玉,李佳蕊.PARP抑制剂在卵巢癌治疗中的研究进展[J].国际妇产科学杂志,2016,43(5):515~518.
[2]Astra Zeneca Pharmaceuticals LP.Lynparza TM(olaparib)capsules,for oral use:US prescribing information[EB/OL].2014.http://www.Accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
[3]MATEO J,CARREIRA S,SANDHU S,et al.DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer[J].N Engl J Med 2015,373:1 697~1 708.
[4]Martin NMB,Smith GCM,Jackson SP,et al.Phthalazinone derivatives[P].WO2004080976,2004-09-23.
[5]Menear KA,Adcock C,Boulter R,et al.4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4fluorobenzyl]-2H-phthalazin-1-one:a novel bioavailable inhibitor of poly(ADP-ribose)polymerase-1[J].J Med Chem,2008,51(20):6 581~6 591.
[6]王立强,邱飞,岳海涛.一种奥拉帕尼中间体的制备方法[P].中国105085408,2015-11-25.
[7]宋柳节,李江,王亚欣等.药物中间体2-氟-5-[(4-氧代-3H-2,3-二氮杂萘基)甲基]苯甲酸的合成工艺改进[J].化学世界,2017,58(2):65~69.
[8]Fuji,K.;Morimoto,T.;Tsutsumi,K.,et al.Rh(I)-catalyzed CO gas-free cyclohydrocarbonylation of alkynes with formaldehyde toα,β-butenolides[J].Chem.commun.,2005,3 295~3 297.
[9]王亚丽,王庆河,杨红光等.酞嗪酮类新型免疫抑制剂的合成与活性研究[J].药学学报,2013,48(10):1 579~1 584.
[2]Astra Zeneca Pharmaceuticals LP.Lynparza TM(olaparib)capsules,for oral use:US prescribing information[EB/OL].2014.http://www.Accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
[3]MATEO J,CARREIRA S,SANDHU S,et al.DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer[J].N Engl J Med 2015,373:1 697~1 708.
[4]Martin NMB,Smith GCM,Jackson SP,et al.Phthalazinone derivatives[P].WO2004080976,2004-09-23.
[5]Menear KA,Adcock C,Boulter R,et al.4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4fluorobenzyl]-2H-phthalazin-1-one:a novel bioavailable inhibitor of poly(ADP-ribose)polymerase-1[J].J Med Chem,2008,51(20):6 581~6 591.
[6]王立强,邱飞,岳海涛.一种奥拉帕尼中间体的制备方法[P].中国105085408,2015-11-25.
[7]宋柳节,李江,王亚欣等.药物中间体2-氟-5-[(4-氧代-3H-2,3-二氮杂萘基)甲基]苯甲酸的合成工艺改进[J].化学世界,2017,58(2):65~69.
[8]Fuji,K.;Morimoto,T.;Tsutsumi,K.,et al.Rh(I)-catalyzed CO gas-free cyclohydrocarbonylation of alkynes with formaldehyde toα,β-butenolides[J].Chem.commun.,2005,3 295~3 297.
[9]王亚丽,王庆河,杨红光等.酞嗪酮类新型免疫抑制剂的合成与活性研究[J].药学学报,2013,48(10):1 579~1 584.